Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases

Atsushi Suzuki, Kensuke Fukumitsu, Jun Fukihara, Takuma Katano, Hisashi Kako, Yuri Maeda, Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Etsuro Yamaguchi

Research output: Contribution to journalArticlepeer-review

Abstract

Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalJournal of Chemotherapy
Volume36
Issue number2
DOIs
Publication statusPublished - 2024

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases'. Together they form a unique fingerprint.

Cite this